S2114: Therapy Following CAR-T (Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if either of two experimental drugs (mosunetuzumab and polatuzumab vedotin) is a safe and effective option for people who have had CAR T-cell therapy. We want to know how each drug works on its own as well as in combination with each other when given after CAR T-cell therapy is complete.
Grade IIIB Follicular or Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with either DLBCL or follicular lymphoma grade 3b
- In the opinion of the study doctor, are a candidate for CAR T-cell therapy and plan to be treated with an FDA-approved CD19 CAR T-cell therapy
For more information about this study, contact the study team at nick.jeffries@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (fair, equal chance) to 1 of 4 groups:
- If you are in Group 1, you will get the study drug mosunetuzumab through a vein in your arm for 8 cycles of treatment. Each cycle is 21 days, or up to 28 days if you need more recovery time between treatments. In cycle 1, you will get this drug on days 1, 8, and 15. First, you will get the pre-medication, dexamethasone. Thirty minutes later, you will get two other pre-medications called acetaminophen and diphenhydramine. One hour after the dexamethasone was given, you will get mosunetuzumab. For cycles 2 through 8, you will only get mosunetuzumab on day 1 of each cycle and not on days 8 and 15. You will get all the pre-medications during cycles 1 and 2. During cycles 3 through 8, you will only receive the pre-medications, acetaminophen and diphenhydramine, unless your study doctor thinks you should continue the dexamethasone.
- If you are in Group 2, you will get the study drug polatuzumab vedotin through a vein in your arm on day 1 of each cycle for 6 cycles of treatment. Each cycle is 21 days.
- If you are in Group 3, you will get both study drugs (mosunetuzumab, and polatuzumab vedotin) through a vein in the arm for up to 8 cycles of treatment. Each cycle is 21 days. In cycle 1, you will receive mosunetuzumab on days 1, 8, and 15. First, you will get the pre-medication, dexamethasone. Thirty minutes later, you will get two other pre-medications called acetaminophen and diphenhydramine. One hour after the dexamethasone was given, you will get mosunetuzumab. In cycles 2 through 7, you will receive mosunetuzumab, and polatuzumab vedotin on day 1. In cycle 8, you will receive mosunetuzumab day 1. During cycles 3 through 8, you will only receive the pre-medications, acetaminophen and diphenhydramine, unless your study doctor thinks you should continue the dexamethasone.
- If you are in Group 4, you will not get any study drugs. You will not receive any treatment after CAR T-cell therapy. The study doctors will closely watch your condition. You will have the option to join Group 3 if your cancer gets worse within 12 months after CAR T-Cell therapy.
Study Details
